1. Zavalishin, I.A. and Peresedova, A.V., Multiple sclerosis: the modern concept of pathogenesis and pathogenetic treatment, Annaly Klinich. Eksp. Nevrol., 2007, no. 1, pp. 32–40.
2. Kappos, L., Weinshenker, B., Pozzilli, C., Thompson, A.J., Dahlke, F., Beckmann, K., Polman, C., and Mcfarland, H., Interferon beta-1b in secondary progressive ms: a combined analysis of the two trials, Neurology, 2004, vol. 63, no. 10, pp. 1779–1787.
3. Alam, J., Goelz, S., Rioux, P., Scaramucci, J., Jones, W., Mcallister, A., Campion, M., and Rogge, M., Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-la (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers, Pharmac. Res., 1997, vol. 14, pp. 546–549.
4. Bertolotto, A., Deisenhammer, F., Gallo, P., and Solberg Sorensen, P., Immunogenicity of interferon beta: differences among products, J. Neurology, 2004, vol. 251, no. 2, pp. 115–124.
5. Pasut, G. and Veronese, F.M., PEG conjugates in clinical development or use as anticancer agents: an overview, Adv. Drug Delivery Rev., 2009, vol. 61, no. 13, pp. 1177–1188.